Jun Gong, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Myovant/Pfizer
    Topic:
    Prostate Cancer
    Date added:
    05/08/2023
    Date updated:
    05/20/2024
    Relationship end date:
    01/28/2022
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Exelixis
    Topic:
    HCC
    Date added:
    05/08/2023
    Date updated:
    05/20/2024
    Relationship end date:
    09/22/2022
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Elsevier
    Topic:
    Renal cell carcinoma
    Date added:
    05/08/2023
    Date updated:
    05/20/2024
    Relationship end date:
    12/31/2022
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    AVEO
    Topic:
    Renal cell carcinoma
    Date added:
    05/08/2023
    Date updated:
    05/20/2024
    Relationship end date:
    10/21/2021
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    EMD Serono
    Topic:
    Bladder cancer
    Date added:
    05/08/2023
    Date updated:
    05/20/2024
    Relationship end date:
    05/27/2021
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Janssen Biotech
    Topic:
    Prostate Cancer
    Date added:
    05/08/2023
    Date updated:
    05/20/2024
    Relationship end date:
    06/17/2021
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Natera
    Topic:
    Colorectal Cancer
    Date added:
    05/08/2023
    Date updated:
    05/20/2024
    Relationship end date:
    05/25/2021
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Bayer
    Topic:
    Colorectal Cancer
    Date added:
    05/08/2023
    Date updated:
    05/20/2024
    Relationship end date:
    05/25/2022
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Incyte
    Topic:
    Cholangiocarcinoma
    Date added:
    05/08/2023
    Date updated:
    05/20/2024
    Relationship end date:
    10/27/2022
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Eisai
    Topic:
    HCC
    Date added:
    05/08/2023
    Date updated:
    05/20/2024
    Relationship end date:
    01/20/2023

Pages

Return to Central California Hematology Oncology Conference: Biomarker Guided Therapy to Improve Patient Outcomes